Vivo BioTech

L i m i t e d www.vivobio.com n proteins for zero disease

Date: 11/08/2016

To

Deputy Manager Dept. of Corporate Services, Bombay Stock Exchange Limited P J Towers, Dalal Street, Fort, MUMBAI – 400001

Dear Sir/Madam,

Sub: Unaudited financial results for the quarter ended on 30th June, 2016

Ref: Reg. 33 of SEBI(Listing obligations and Disclosure Requirements)

Regulations, 2015 Agreement, Script Code# 511509

With reference to subject cited above please find enclosed Unaudited financial results for the quarter the quarter ended on 30th June , 2016 as per the Reg.33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Report issued by the Statutory Auditors of the company

This is for your record and reference.

Thanking you,

Yours faithfully,

For Vivo Big Fech Limited

M Kalyan Kam Whole Time Director

DIN: 02012580

Sy. No: 349/A, 350/A, 351, 356/3A (SEZ-Special Economic Zone) Village: Pregnapur,

Gajwel Mandal, Medak District, Andhra Pradesh. INDIA # 608, 6th Floor, Lingapur Complex, Himayat Nagar, Hyderabad - 500 029. A.P., INDIA Ph. : +91 (40) 66784714, 66784719 Fax : +91-40-66776112

CIN NO: 1659937G1987PLC007163

Vivo BioTech

m www.vivobio.com n proteins for zero disease

Unaudited Financial Results for the quarter ended on 30/06/2016					Rs. In Lakh
	and the quarte				
S.No.	PARTICULARS		UARTER ENDED		YEAR ENDED
		30.06.2016	31.03.2016		31.03.2016
	1 Income from Operations	Unaudited	Audited	Unaudited	Audited
	a) Net Sales/ Income from Operations				
	b) Other Operating Income	623.32	735.09	605.22	2851.90
	Total Income from operations	194.87	0.00	0.00	6.43
2	Expenses	818.19	735.09	605.22	2858.33
	a. Increase/(decrease) in stock in trade and WIP	122.40			
	b. Consumption of Raw materials	122.40	50.56	0.00	60.56
	c. Purchase of traded goods	205.00	42.73	190.08	819.29
	d. Employees Cost	0.00	0.00	0.00	0.00
	e. Depreciation	131.68	127.35	88.08	434.26
	f. Other Expenditure	83.85	91.68	76.16	335.40
	1.Administrative Expenditure	0.00	0.00		
	g. Total	237.61	448.65	210.79	1173.46
	Profit/loss from Operations before other income, finance cost and	780.54	760.97	565.11	2822.97
3	exceptions items(1-2)				
	Other income	37.65	-25.88	40.11	35.36
	Profit/(loss) from Ordinary activities before finance costs and	23.37	31.58	17.89	89.25
5	exceptional items(3+4)				
	Finance costs	61.02	5.69	58.00	124.61
	Profit/(loss) from Ordinary activities after finance costs but before	9.63	15.54	9.60	46.57
7	exceptional items(5-6)				
	Exceptional items	51.39	-9.85	48.40	78.04
	Profit/Loss from Ordinary Activities before tax(7-8)	0.00	0.00	0.00	0.00
10	Tax Expense	51.39	-9.85	48.40	78.04
	Net Profit/Loss from Ordinary Activities after Tax(9-10)	11.31	-39.32	14.52	-12.96
12	Extraordinary Items (Net of Tax expense of RsLakh)	40.09	29.47	33.88	91.00
13	Net Profit/Loss for the Period(11-12)	0.00	0.00	0.00	0.00
14	Paid IIn Share Conite (Ferral V. L Salara V. L	40.09	29.47	33.88	91.00
1	Paid Up Share Capital(Face Value of Rs.10/-each)	935.05	935.05	935.05	935.05
15 r	Reserves Excluding Revaluation Reserves as per Balance sheet of previous accouting year				
i E		0.00	0.00	0.00	0.00
	arning Per Share(EPS)(Before Extraordinary items))Basic				
)Diluted	0.43	0.32	0.36	0.97
		0.43	0.32	0.36	0.97
а	arning Per Share(EPS)(After Extraordinary items)) Basic				
) Diluted	0.43	0.32	0.36	0.97
) Diluteu	0.43	0.32	0.36	0.97

Date:11th August, 2016 Place: Hyderabad

Sy. No: 349/A, 350/A, 351, 356/3A (SEZ-Special Economic Zone) Village : Pregnapur,

Gajwel Mandal, Medak District, Andhra Pradesh. INDIA

For Wyo Bio Tech Limited Hyderabad M Kalyan Ram

DIN: 0201# 608, 6th Floor, Lingapur Complex, Himayat Nagar, Hyderabad - 500 029. A.P., INDIA Ph.: +91 (40) 66784714, 66784719 Fax: +91-40-66776112

CEN NO: L6 59937G1987P1C007463

Vivo BioTech

L i m i t e d www.vivobio.com n proteins for zero disease

Notes:

- The above financial results are recommended by the Audit Committee were considered and approved by the board of directors at their meeting held on 11th August, 2016.
- 2. In accordance with the Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, Statutory Auditors have performed limited review of the financial results of M/s. Vivo Bio Tech Limited for the quarter ended 30th June, 2016. There are no qualifications in the limited review report issued for the said period
- 3. The Entire operations of the company relate to single segment viz., Bio Technology. Hence Segmental reporting as per AS-17 is not made.
- 4. Previous year's/period's figures are rearranged/ regrouped wherever necessary


Date:11th August, 2016 Place: Hyderabad For Vivo Bio Tech Limited

M-Kalyan Ram Whole Time Director DIN: 02012580

Sy. No : 349/A, 350/A, 351, 356/3A (SEZ-Special Economic Zone) Village : Pregnapur,

Gajwel Mandal, Medak District, Andhra Pradesh. INDIA # 608, 6th Floor, Lingapur Complex, Himayat Nagar, Hyderabad - 500 029. A.P., INDIA Ph.: +91 (40) 66784714, 66784719 Fax: +91-40-66776112

CIN NO: 4659937G/987PC007/63



Tel. : (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

: (91-40) 2339 2474 Fax E-mail

: pmurali.co@gmail.com

info@pmurali.com Website: www.pmurali.com

Limited Review Report

To The Board of Directors Vivo Bio Tech Limited Hyderabad.

Limited Review Report for the quarter ended 30th June, 2016.

We have reviewed the accompanying Statement of Unaudited Financial Results of Vivo Bio Tech Limited for the Period/Quarter I Ended 30th June 2016. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of interim financial information performed by the independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

MURALIC

For P. Murali & Co., Chartered Accountants

Firm Registration No: 007257

A. Krishna Rao

Partner

Membership No. 020085

Place: Hyderabad Date: 11/08/2016